Key metrics to expanding the pipeline of successful antibody–drug conjugates
I Nessler, B Menezes, GM Thurber - Trends in pharmacological sciences, 2021 - cell.com
Although the recent FDA approval of six new antibody–drug conjugates (ADCs) is
promising, attrition of ADCs during clinical development remains high. The inherent …
promising, attrition of ADCs during clinical development remains high. The inherent …
[HTML][HTML] Modeling pharmacokinetics and pharmacodynamics of therapeutic antibodies: progress, challenges, and future directions
Y Tang, Y Cao - Pharmaceutics, 2021 - mdpi.com
With more than 90 approved drugs by 2020, therapeutic antibodies have played a central
role in shifting the treatment landscape of many diseases, including autoimmune disorders …
role in shifting the treatment landscape of many diseases, including autoimmune disorders …
Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy
BM Bordeau, Y Yang, JP Balthasar - Cancer research, 2021 - AACR
Poor penetration of mAbs in solid tumors is explained, in part, by the binding site barrier
hypothesis. Following extravasation, mAbs rapidly bind cellular antigens, leading to the …
hypothesis. Following extravasation, mAbs rapidly bind cellular antigens, leading to the …
Spatiotemporal quantification of HER2-targeting antibody–drug conjugate bystander activity and enhancement of solid tumor penetration
Q Wei, T Yang, J Zhu, Z Zhang, L Yang, Y Zhang… - Clinical Cancer …, 2024 - AACR
Purpose: Antibody–drug conjugate (ADC) has had a transformative effect on the treatment of
many solid tumors, yet it remains unclear how ADCs exert bystander activity in the tumor …
many solid tumors, yet it remains unclear how ADCs exert bystander activity in the tumor …
[HTML][HTML] A framework for multi-scale intervention modeling: virtual cohorts, virtual clinical trials, and model-to-model comparisons
CT Michael, SA Almohri, JJ Linderman… - Frontiers in Systems …, 2024 - frontiersin.org
Computational models of disease progression have been constructed for a myriad of
pathologies. Typically, the conceptual implementation for pathology-related in silico …
pathologies. Typically, the conceptual implementation for pathology-related in silico …
Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data
B Rubahamya, S Dong, GM Thurber - Science Advances, 2024 - science.org
Antibody drug conjugates (ADCs) have made impressive strides in the clinic in recent years
with 11 Food and Drug Administration approvals, including 6 for the treatment of patients …
with 11 Food and Drug Administration approvals, including 6 for the treatment of patients …
Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2–positive …
B Menezes, JJ Linderman, GM Thurber - Drug Metabolism and Disposition, 2022 - ASPET
Intratumoral heterogeneity is a leading cause of treatment failure resulting in tumor
recurrence. For the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) …
recurrence. For the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) …
[HTML][HTML] Development and evaluation of competitive inhibitors of trastuzumab-HER2 binding to bypass the binding-site barrier
BM Bordeau, L Abuqayyas, TD Nguyen… - Frontiers in …, 2022 - frontiersin.org
Our group has developed and experimentally validated a strategy to increase antibody
penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior …
penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior …
[HTML][HTML] Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
B Scheuher, KR Ghusinga, K McGirr, M Nowak… - … of pharmacokinetics and …, 2023 - Springer
A next generation multiscale quantitative systems pharmacology (QSP) model for antibody
drug conjugates (ADCs) is presented, for preclinical to clinical translation of ADC efficacy …
drug conjugates (ADCs) is presented, for preclinical to clinical translation of ADC efficacy …
[HTML][HTML] Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
R Evans, GM Thurber - Scientific Reports, 2022 - nature.com
Abstract Antibody-Drug Conjugates (ADCs) have rapidly expanded in the clinic, with 7 new
approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and …
approvals in 3 years. For solid tumors, high doses of ADCs improve tissue penetration and …